Investor Readiness for Medical Device Founders: The 7 Questions VCs Will Ask That You're Not Prepared For

← Back to All Insights

You've spent months refining your pitch deck. Problem, solution, market size, team, traction—it's all tight. Your clinical data is compelling. Your prototype works. You've got letters of intent from potential customers. You feel ready to fundraise.

Then you walk into a VC meeting and get asked a question you haven't prepared for. The investor leans back and asks: "What's your predicate device strategy and what's the risk of an additional information request from FDA?" You stumble. You've focused on clinical validation; you haven't thought deeply about FDA regulatory risk or what happens if they ask for more data. The meeting doesn't end well.

This happens to medtech founders constantly. Most founders prepare thoroughly for the obvious questions—problem, solution, market opportunity, competitive advantage. But when VCs dig into technical due diligence, they ask seven critical questions that founders haven't prepared for. And stumbling on these questions kills deals.

Here are the seven questions VCs will ask, what they're actually trying to learn, the common founder mistake, and how to prepare.

Question 1: "What's Your Predicate Device Strategy and What's the Risk of an Additional Information Request?"

What VCs are really learning: FDA regulatory risk. Investors know that FDA delays kill companies. A 12-month delay in clearance can drain your runway and force down valuation. VCs want to know you've thought deeply about predicate risk, not just identified a predicate device.

The common founder mistake: You say: "We've identified a predicate device that's similar to ours." The investor probes: "What's the risk that FDA denies your 510(k) and forces you into De Novo?" You look confused. You haven't prepared for that scenario. You thought your predicate was solid.

How to prepare: Before any VC meeting, identify your predicate device in writing. Include: (1) the predicate's specific clearance pathway and date, (2) your analysis of why your device is substantially equivalent to the predicate in intended use AND technological characteristics, (3) your predicate risk assessment—what could cause FDA to question your substantial equivalence claim, and (4) your mitigation plan if FDA issues an information request or denies your 510(k).

The investor won't expect you to have perfect FDA answers, but they will expect you to have thought about regulatory risk seriously. If you haven't, they'll assume you're underprepared.

Question 2: "What Does Your Clinical Evidence Roadmap Look Like Beyond 510(k) Clearance?"

What VCs are really learning: Post-clearance commercialization strategy. Getting FDA cleared is table stakes—it's step 1. But hospitals won't buy your device based on FDA clearance alone. Value analysis committees want clinical outcomes data showing your device improves patient outcomes or reduces costs compared to alternatives. VCs want to know you have a plan for generating that post-market data.

The common founder mistake: You assume "FDA clearance = market adoption." You've invested heavily in generating clinical data to support your FDA submission, but you haven't thought about what clinical evidence hospitals will need to approve your device. The investor asks about your clinical evidence roadmap beyond FDA, and you realize you don't have one.

How to prepare: Before VC conversations, map out your clinical evidence roadmap. Include: (1) what clinical outcomes will hospitals and payers care about (mortality, morbidity, cost reduction, length of stay), (2) what studies or post-market surveillance data you'll need to generate, (3) the timeline and cost to generate that data, and (4) how that data will drive hospital adoption.

For many devices, the real market adoption happens 12-24 months after FDA clearance, once you have clinical evidence that hospitals trust. VCs want to see that you've budgeted for this roadmap.

Question 3: "Who Pays for This and How?"

What VCs are really learning: Reimbursement strategy. This is the "unfundable" moment for many medtech companies. You have a brilliant device, but if no one will pay for it, you have a hobby, not a business.

The common founder mistake: You say: "Hospitals will buy this because it improves patient outcomes." The investor asks: "At what price point? What CPT code will be used? What's the reimbursement pathway?" You don't have answers. You're assuming the reimbursement piece will work out, but you haven't validated it.

How to prepare: Before fundraising, research your reimbursement landscape. Identify: (1) the specific CPT or HCPCS codes that will be used for billing your device, (2) what Medicare's reimbursement rate is for those codes (you can look this up on CMS.gov), (3) what private insurers typically reimburse for comparable procedures, (4) whether your device will be reimbursed as a consumable, as a procedure add-on, or as a capital equipment purchase, and (5) what the coverage decision timeline looks like.

You don't need to have the entire reimbursement strategy locked in, but you need to demonstrate that you've thought about it. VCs have seen too many medtech companies with great devices that couldn't generate revenue because reimbursement was unfavorable.

Question 4: "What Happens When Your Contract Manufacturer Can't Scale?"

What VCs are really learning: Manufacturing and supply chain risk. Most early-stage medtech companies use contract manufacturers. That's fine. But VCs want to know you've thought about what happens if your manufacturer can't scale to meet commercial demand, or if they raise prices dramatically once you're dependent on them.

The common founder mistake: You've got a contract manufacturer building your prototype, and you assume they'll scale to commercial volumes. You haven't thought about single-source risk, design transfer complexity, or COGS at volume. An investor asks about manufacturing risk, and you realize you've made a handshake agreement with your manufacturer but haven't thought strategically about scaling.

How to prepare: Quantify your manufacturing plan: (1) What's your current COGS at prototype volumes? (2) What's your projected COGS at commercial volumes (5,000, 10,000, 50,000 units per year)? (3) Have you conducted design transfer planning with your manufacturer? (4) Do you have a backup manufacturer identified, or are you single-source dependent? (5) What's your lead time for ramping to production, and what's your safety stock strategy?

You don't need to have this all figured out perfectly, but demonstrating that you've thought about manufacturing risk signals competence. VCs have seen companies implode because they couldn't scale manufacturing fast enough to meet demand.

Question 5: "What's Your IP Moat Beyond the Core Patent?"

What VCs are really learning: Competitive defensibility. A single patent can be designed around. VCs want to know you have multiple layers of IP protection: trade secrets, design patents, regulatory exclusivity (e.g., 510(k) pathway, De Novo designation), and brand/market presence.

The common founder mistake: You've filed one utility patent on your core technology. When an investor asks about your IP strategy, you focus on the patent. They probe deeper: "What about freedom to operate? What if a competitor designs around your patent? What trade secrets are protecting your manufacturing process?" You realize you haven't thought about broader IP strategy.

How to prepare: Develop a comprehensive IP strategy document: (1) List your core patents with filing dates and expected grant dates, (2) Identify any secondary IP (design patents, continuation applications), (3) Conduct a freedom-to-operate analysis—are there competitor patents that could block you? (4) Identify your trade secrets and how you're protecting them, (5) Understand your regulatory exclusivity (510(k) vs. De Novo has different competitive moats).

VCs are looking for evidence that you have a durable competitive advantage, not just a single patent.

Question 6: "Show Me Your Post-Market Surveillance Plan"

What VCs are really learning: Post-clearance risk management. FDA requires post-market surveillance for most medical devices. If you find adverse events post-market, you need a plan to respond. A bad post-market signal can destroy your company (think of the early problems with some orthopedic implants when post-market data revealed higher-than-expected complication rates).

The common founder mistake: You've focused entirely on pre-market validation. You haven't thought about post-market surveillance. The investor asks: "What's your plan if you find a safety signal in post-market data?" and you don't have a credible answer. The investor gets nervous—you're thinking about sales, not about managing risk.

How to prepare: Develop a post-market surveillance plan: (1) What will you monitor? (adverse events, complications, device failures), (2) How will you collect post-market data? (patient registries, hospital reports, active surveillance), (3) What's your threshold for investigating a potential safety signal? (4) Who is responsible for regulatory reporting if you find a problem? (5) What's your timeline for responding to FDA inquiries about post-market data?

A mature post-market surveillance plan signals that you're thinking about long-term risk management, not just short-term sales.

Question 7: "What Does Your Quality System Look Like?"

What VCs are really learning: Operational maturity and regulatory compliance. FDA doesn't just regulate your device; it regulates how you manufacture, test, and document everything. A poor quality system creates regulatory risk and can trigger FDA warning letters or recalls.

The common founder mistake: You've built a functioning prototype in a lab environment. You haven't thought about ISO 13485 certification, design history files, or CAPA (corrective action preventive action) processes. An investor asks about your quality system, and you realize you're flying by the seat of your pants with documentation and testing.

How to prepare: Assess your quality system maturity: (1) Are you ISO 13485 certified or on a path to certification? (2) Do you have a design history file that documents all design decisions and testing? (3) Do you have a bill of materials with supplier qualification? (4) Do you have procedures for design changes, testing, and risk management? (5) Do you have a CAPA process for handling deviations?

How a Vantage Assessment Answers All 7 Questions Proactively

If you've been thinking: "I haven't prepared answers to most of these questions," you're not alone. Most medtech founders focus on technical innovation and clinical validation, then get blindsided by VCs asking about regulatory pathways, reimbursement, and manufacturing risk.

A Vantage Assessment systematically evaluates all seven dimensions: regulatory risk, clinical evidence strategy, reimbursement landscape, manufacturing readiness, IP defensibility, post-market risk, and quality system maturity. When you complete the assessment, you walk into VC meetings with answers to the questions VCs will ask.

Beyond that, you can share the Vantage Score with investors. It signals that an independent clinical-technical team has validated your assumptions. Early-stage companies without revenue or clinical data need that third-party credibility. A strong Vantage Score can be the difference between a meeting and a pass.

The Bottom Line for Founders

Your pitch deck matters. Your clinical data matters. Your team credentials matter. But when VCs dig into technical due diligence, the seven questions above will determine whether they write you a check. Prepare answers to all seven before your first investor meeting. The founders who do this advance confidently through diligence. The ones who don't stumble when it matters most.

"The best time to think about FDA risk, reimbursement, and manufacturing is before you're in a VC meeting scrambling for answers."

Need a Custom Analysis?

Our proprietary risk framework has been validated against documented medical device companies. Get a complimentary regulatory readiness assessment for your submission strategy.

Schedule Free Discovery Call Download Free Red Flags Guide